Baxter Web-Enabled Device Development Starting With Renal Dialysis
This article was originally published in The Gray Sheet
Executive Summary
Baxter projects the growth rate of its renal business will accelerate to 15% "over the next several years" from its current growth rate of "10 to 12%" in part due to web-enabled devices under development.
You may also be interested in...
Baxter Expects To Roughly Double Renal Business By 2005 To $3.5 Bil.
Baxter says it plans to approximately double the size of its renal business to $3.5 bil. annually by 2005, from $1.8 bil. in 2000, increasing the unit's annual growth rate to about 15% over the next several years from the current 9% level, the firm says.
Baxter Expects To Roughly Double Renal Business By 2005 To $3.5 Bil.
Baxter says it plans to approximately double the size of its renal business to $3.5 bil. annually by 2005, from $1.8 bil. in 2000, increasing the unit's annual growth rate to about 15% over the next several years from the current 9% level, the firm says.
Edwards Lifesciences Lifepath AAA Graft Fracture Investigation Ongoing
Edwards Lifesciences is continuing to investigate the cause of fractures detected in the wireform scaffolding of its Lifepath endovascular graft system for treatment of abdominal aortic aneurysms, following discovery of the fractures in two patients treated with the device.